Home     About Us     Team     Products     News     Contact     FAQ     Account

Bruton Tyrosine Kinase (BTK) Inhibitors


Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that binds permanently to a protein, Bruton's tyrosine kinase (BTK), that is important in B cells. It is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia...Wikipedia



Manufacturer's Website: Imbruvica                                                                                                                        Average retail cost:   $13,500/month

Brukinsa (zanubrutinib)

Zanubrutinib, sold under the brand name Brukinsa, is for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It was approved for medical use in the United States in November 2019. Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor




Manufacturer's Website: Brukinsa                                                                                                                       Average retail cost:   $13,500/month

Calquence (acalabrutinib)

Acalabrutinib, sold under the brand name Calquence, is a medication used to treat a type of non-Hodgkin lymphoma known as mantle cell lymphoma. Specifically it is for people who had previously been treated with another therapy. As of 2019, it was unclear whether it improved outcomes...Wikipedia



Manufacturer's Website: Calquence                                                                                                                       Average retail cost:   $14,700/month

Copyright 2006-2022 Automated Clinical Guidelines, LLC. All rights reserved.